|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,400 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: LUPRON DEPOT-PED
Summary for Tradename: LUPRON DEPOT-PED
|
| |||||||||
Clinical Trials for: LUPRON DEPOT-PEDSafety Extension Study Of Lupron Depot In The Treatment Of Central Precocious Puberty Status: Completed Condition: Precocious; Leuprolide Acetate; Luteinizing Hormone (LH); Gonadotrophin-releasing Hormone Agonist(GnRHa); Tanner Staging; Depot Formulation; Suppression of LH; CPP; Gonadotrophin-releasing Hormone (GnRH); Lupron; GnRH Analog; Pediatrics Central Precocious Puberty A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty Status: Completed Condition: Puberty, Precocious Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy Status: Completed Condition: Prostatic Neoplasms A Study of Leuprolide to Treat Prostate Cancer Status: Completed Condition: Prostate Cancer Melanoma Vaccine With Peptides and Leuprolide Status: Completed Condition: Melanoma Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer Status: Completed Condition: Prostatic Neoplasm Study of Lupron Depot In The Treatment of Central Precocious Puberty Status: Completed Condition: Puberty, Precocious Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS) Status: Completed Condition: Advanced Prostate Cancer; Lower Urinary Tract Symptoms Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Status: Recruiting Condition: Fibrolamellar Carcinoma; Fibrolamellar Liver Cancer A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Status: Completed Condition: Cancer of Prostate Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbott Endocrine | LUPRON DEPOT-PED | leuprolide acetate | INJECTABLE; INJECTION | 020263 | Apr 16, 1993 | DISCN | No | 5,575,987 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abbott Endocrine | LUPRON DEPOT-PED | leuprolide acetate | INJECTABLE; INJECTION | 020263 | Apr 16, 1993 | DISCN | No | 5,631,020 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abbott Endocrine | LUPRON DEPOT-PED | leuprolide acetate | INJECTABLE; INJECTION | 020263 | Apr 16, 1993 | DISCN | No | 5,716,640 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abbott Endocrine | LUPRON DEPOT-PED | leuprolide acetate | INJECTABLE; INJECTION | 020263 | Apr 16, 1993 | DISCN | No | 6,036,976 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc
